PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth ...
(RTTNews) - Alcon, a division of Novartis, announced it has received approval from the US FDA for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ACTIVEFOCUS optical design for ...
Please provide your email address to receive an email when new articles are posted on . PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, ...
Disclaimer: This is sponsored content paid for by Vision for Life. All opinions and views are of the advertiser and does not reflect the same of NewsChannel 5 Nashville. In today’s Your Health Matters ...
TORONTO, Nov. 17, 2020 /CNW/ - Alcon, the global leader in eye care, is pleased to announce the Canadian launch of AcrySof ® IQ Vivity ®, a first-of-its-kind, surgical lens designed to help cataract ...
Basel, Switzerland, July 1, 2015 – Alcon, the global leader in eye care and a division of Novartis, has received European CE Mark for its AcrySof® IQ Aspheric IOL with the UltraSert™ Pre-loaded ...
Please provide your email address to receive an email when new articles are posted on . A prospective comparative case series of 50 patients implanted bilaterally ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
Lance Kugler, MD, of Omaha, Neb.-based Kugler Vision, is slated to be the first surgeon in eastern Nebraska to use Acrysof IQ Vivity Lens from Geneva, Switzerland-based Alcon, according to an Oct. 27 ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...